Budesonide-Formoterol Reliever Therapy In Intermittent Versus Mild Persistent Asthma

Traditional asthma maintenance therapy in adults and adolescents comprises inhaled corticosteroids (ICS), with a long-acting β2-agonist (LABA) added if ICS monotherapy provides insufficient control [1, 2].\n\nFootnotes \n\nThis manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.\n\nConflict of interest: Dr. Papi reports grants and personal fees from MRINZ, during the conduct of the study; grants, personal fees, non-financial support and other from GlaxoSmithKline, grants, personal fees and non-financial support from AstraZeneca, grants, personal fees, non-financial support and other from Boehringer Ingelheim, grants, personal fees, non-financial support and other from Chiesi Farmaceutici, grants, personal fees, non-financial support and other from TEVA, personal fees, non-financial support and other from Mundipharma, personal fees, non-financial support and other from Zambon, personal fees, non-financial support and other from Novartis, grants, personal fees and non-financial support from Menarini, personal fees, non-financial support and other from Sanofi/Regeneron, personal fees from Roche, grants from Fondazione Maugeri, grants from Fondazione Chiesi, personal fees from Edmondpharma, outside the submitted work.\n\nConflict of interest: Dr. Braithwaite reports grants from Astra Zeneca, grants from Health Research Council of New Zealand, during the conduct of the study.\n\nConflict of interest: Dr. Ebmeier reports grants from MRINZ, during the conduct of the study.\n\nConflict of interest: Dr. Hancox reports personal fees from Menarini, personal fees and other from Astra Zeaneca, other from Boehringer Ingelheim, during the conduct of the study.\n\nConflict of interest: Dr. Harrison reports grants from MRINZ, during the conduct of the study; grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from GSK, personal fees from Vectura, personal fees from Synairgen, personal fees from Chiesi, outside the submitted work.\n\nConflict of interest: Mr. Holliday reports grants from Health Research Council of New Zealand, grants from AstraZeneca, during the conduct of the study.\n\nConflict of interest: Dr. Houghton reports grants from Health Research Council of New Zealand, grants and personal fees from AstraZeneca, during the conduct of the study.\n\nConflict of interest: Dr. Morandi reports grants from MRINZ, during the conduct of the study.\n\nConflict of interest: Dr. Oldfield reports grants to MRINZ from the Health Research Council of New Zealand, grants from AstraZeneca, during the conduct of the study; she has nothing personal to disclose.\n\nConflict of interest: Dr. Pavord reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Aerocrine, personal fees from Almirall, personal fees from Novartis, personal fees from GlaxoSmithKline, personal fees from Genentech, personal fees from Regeneron, from Teva, from Chiesi, from Sanofi, from Circassia, from Knopp, grants from NIHR, outside the submitted work.\n\nConflict of interest: Dr. Reddel reports grants from AstraZeneca, grants from Health Research Council of New Zealand, during the conduct of the study; grants and personal fees from AstraZeneca, grants and personal fees from GlaxoSmithKline, personal fees from Merck, personal fees from Novartis, personal fees from Teva, personal fees from Boehringer Ingelheim, personal fees from Sanofi Genzyme, outside the submitted work; and Dr Reddel is Chair of the GINA Science Committee.\n\nConflict of interest: Mr. Williams reports grants from MRINZ, during the conduct of the study; personal fees from Genentech Respiratory Operational Review Board, outside the submitted work.\n\nConflict of interest: Dr. Weatherall has nothing to disclose.\n\nConflict of interest: Dr. Beasley reports grants from Health Research Council of New Zealand, grants and personal fees from AstraZeneca, during the conduct of the study; grants and personal fees from AstraZeneca, grants from GlaxoSmithKline, grants from Genentech, personal fees from Theravance Biopharma, outside the submitted work.